Comparative Pharmacology
Head-to-head clinical analysis: ORTHO TRI CYCLEN 28 versus ORTHO NOVUM 10 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO TRI CYCLEN 28 versus ORTHO NOVUM 10 21.
ORTHO TRI-CYCLEN 28 vs ORTHO-NOVUM 10-21
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination of ethinyl estradiol and norgestimate primarily suppresses gonadotropin (FSH and LH) secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial structure to impede fertilization and implantation.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining, reducing sperm penetration and implantation.
FDA-approved: Prevention of pregnancyOff-label: Treatment of moderate acne vulgaris in females ≥15 years of age who have no known contraindications and desire oral contraception
Prevention of pregnancyTreatment of menorrhagiaTreatment of dysmenorrheaRegulation of menstrual cyclesEmergency contraception (off-label)
One tablet daily for 28 days: 21 active tablets (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg, norgestimate 0.215 mg/ethinyl estradiol 0.035 mg, norgestimate 0.250 mg/ethinyl estradiol 0.035 mg) followed by 7 inert tablets. Route: oral.
1 tablet (1 mg norethindrone, 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of no tablets.
None Documented
None Documented
Norethindrone: ~8 hours; Ethinyl estradiol: ~15 hours (biphasic, terminal: 15-20 hours). Steady-state achieved within 7-14 days.
Norethindrone 5-14 hours (mean 8 hours), ethinyl estradiol 7-20 hours (mean 13 hours). Steady-state achieved in 5-10 days.
Ethinyl estradiol undergoes oxidative metabolism primarily via CYP3A4 and undergoes conjugation (glucuronidation and sulfation). Norgestimate is extensively metabolized to its active metabolite norelgestromin via first-pass hepatic (hydrolysis) and further to levonorgestrel; norelgestromin is metabolized by CYP3A4 and CYP2C9.
Hepatic via cytochrome P450 3A4 (CYP3A4) for norethindrone and ethinyl estradiol; first-pass metabolism; enterohepatic recirculation; elimination as glucuronide and sulfate conjugates in urine and feces.
Renal: ~60% (metabolites); Fecal: ~40% (metabolites); unchanged drug <1%
Renal approximately 50-60% as metabolites, biliary/fecal approximately 30-40% as metabolites and unchanged drug.
Norethindrone: ~97% (albumin, SHBG); Ethinyl estradiol: ~98% (albumin, SHBG).
Norethindrone: 90-95% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: 3-4 L/kg; Ethinyl estradiol: 2-3 L/kg. Indicates extensive tissue distribution.
Norethindrone: 4 L/kg; ethinyl estradiol: 2-4 L/kg; indicates extensive tissue distribution.
Norethindrone: ~65% (first-pass metabolism); Ethinyl estradiol: ~45% (first-pass metabolism).
Oral: norethindrone 50-80%, ethinyl estradiol 40-60% due to first-pass metabolism.
No specific GFR-based dose adjustments established. Use with caution in severe renal impairment (GFR <30 mL/min) due to potential fluid retention and electrolyte disturbances.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (GFR <30 mL/min) due to lack of safety data.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). No data for Child-Pugh A; use with caution.
Contraindicated in Child-Pugh class B or C hepatic impairment. For Child-Pugh class A, use with caution and monitor liver function; no specific dose adjustment established.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy not established in pediatric patients under 18 years for contraception.
Not indicated for use in pediatric patients before menarche. Post-menarche: same adult dosing, 1 tablet orally once daily for 21 days, then 7 days off.
Not indicated for use in postmenopausal women. No specific dosing adjustments; risks of thromboembolic events outweigh benefits in women over 35 who smoke or have cardiovascular risk factors.
Not indicated for use in postmenopausal women. Not recommended for elderly patients due to lack of efficacy and increased thrombotic risk.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
["Thromboembolic disorders: increased risk of venous thromboembolism and arterial thrombosis","Cigarette smoking increases cardiovascular risk","Hypertension: may cause or worsen hypertension","Gallbladder disease: increased risk of gallbladder disease","Hepatic tumors: risk of hepatic adenomas (rare) and possible hepatocellular carcinoma","Carbohydrate and lipid effects: may affect glucose tolerance and lipid profile","Ocular lesions: retinal thrombosis (discontinue if unexplained vision loss occurs)","Depression: may precipitate or worsen depression","Bleeding irregularities: breakthrough bleeding and spotting common","Hereditary angioedema: may exacerbate symptoms"]
Increased risk of thromboembolic disorders (e.g., DVT, pulmonary embolism), myocardial infarction, stroke; hepatic neoplasia (benign and malignant); gallbladder disease; hypertension; glucose intolerance; elevated triglyceride levels; exacerbation of depression; fluid retention; headache; irregular bleeding; potential for decreased efficacy with concomitant enzyme-inducing drugs; instruct to report visual disturbances or migraine; discontinue if jaundice occurs; monitor for signs of thrombosis.
["Known or suspected pregnancy","Current or past thrombophlebitis or thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism)","Current or past arterial thromboembolic disease (e.g., stroke, myocardial infarction)","Cerebrovascular disease","Known or suspected breast carcinoma or other estrogen- or progestin-sensitive cancer","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenomas or carcinomas","Known liver disease or impaired liver function, including active viral hepatitis","Uncontrolled hypertension (>160/100 mmHg)","Diabetes with vascular involvement","Headaches with focal neurological symptoms (e.g., migraine with aura)","Major surgery with prolonged immobilization","Smoking in women over 35 years","Hypersensitivity to any component of the product"]
Thrombophlebitis or thromboembolic disorders; history of DVT or PE; cerebrovascular or coronary artery disease; known or suspected breast cancer; endometrial cancer or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; known or suspected pregnancy; liver tumors (benign or malignant) or active liver disease; hypersensitivity to any component; age >35 years and smoking cigarettes; uncontrolled hypertension; diabetes with vascular involvement; migraine with focal aura; major surgery with prolonged immobilization.
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically relevant. Maintain consistent dietary habits to avoid variability in absorption.
No significant food interactions. Grapefruit juice may increase estrogen levels but clinical relevance is minimal. Avoid excessive alcohol consumption due to potential liver strain. Maintain consistent dietary habits to reduce gastrointestinal side effects.
Pregnancy category X. Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and oral clefts. Second and third trimesters: association with fetal genital abnormalities (e.g., hypospadias in males, virilization of female fetuses). No safe use established.
Pregnancy category X. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second and third trimesters: associated with fetal adrenal suppression, virilization of female fetuses, and potential for long-term neurodevelopmental effects. Use contraindicated in pregnant women.
Not recommended during breastfeeding. Combined hormonal contraceptives reduce milk production and nutrient content. Limited ethinyl estradiol and norgestimate transfer into breast milk; M/P ratio not well defined. Use alternative contraception.
Excreted into breast milk in small amounts (M/P ratio approximately 0.5). May reduce milk production and composition. Use during breastfeeding not recommended; alternative contraception advised.
No dose adjustment applicable; contraindicated in pregnancy. If exposure occurs, discontinue immediately. No pharmacokinetic data indicate safe use or dose modifications during pregnancy.
Contraindicated in pregnancy; no dosing adjustments are applicable. Discontinue immediately if pregnancy occurs.
Category C
Category C
Ortho Tri-Cyclen 28 is a triphasic oral contraceptive containing norgestimate and ethinyl estradiol. The triphasic dosing mimics natural hormonal fluctuations and may reduce breakthrough bleeding. It is also FDA-approved for moderate acne vulgaris in women at least 15 years old who desire contraception. Monitor for thromboembolic events, especially in smokers over 35. CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy. Advise backup contraception during concurrent antibiotic use.
ORTHO-NOVUM 10-21 (norethindrone 10 mg with ethinyl estradiol 21 mcg) 21-day regimen: breakthrough bleeding/spotting is common during first 3 cycles; encourage continuation. If a dose is missed, take as soon as remembered and use backup contraception for 7 days. Higher estrogen content increases thromboembolic risk; avoid in smokers >35 years. Monitor blood pressure and liver function at baseline and periodically.
Take one pill daily at the same time, preferably after a meal.The 28-day pack has 21 active pills and 7 placebo pills; always start a new pack immediately after finishing the previous one.If you miss a pill, check the package insert: take missed pill as soon as remembered and use backup contraception.Common side effects include nausea, breast tenderness, and breakthrough bleeding; these often improve after 3 months.Seek medical attention for severe headache, vision changes, leg pain, or shortness of breath (thrombosis symptoms).Do not smoke while taking this medication, as it increases risk of blood clots and stroke.This pill does not protect against sexually transmitted infections (STIs).
Take one tablet daily at the same time for 21 days, then 7 pill-free days.Use backup contraception (e.g., condoms) for the first 7 days of the first pack.If you miss a pill, take it as soon as you remember; if more than 24 hours, take last missed and use backup for 7 days.Common side effects include nausea, breast tenderness, spotting, and mood changes; they often improve within 3 months.Seek medical attention for severe leg pain, chest pain, shortness of breath, or severe headache.Do not smoke while taking this medication, especially if over 35 years old.